The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
Axsome is heading to regulators in the wake of a second successful depression study, and investors are predicting huge success. What could possibly go wrong?
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Alcohol kills – and in this case, that could be a good thing.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.